May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Excess Endogenous VEGF–A Suppresses Laser–induced Choroidal Neovascularization via VEGFR–1
Author Affiliations & Notes
  • M. Nozaki
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY
  • E. Sakurai
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY
  • B.J. Raisler
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY
  • J.Z. Baffi
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY
  • M. Shibuya
    Institute of Medical Science, University of Tokyo, Tokyo, Japan
  • B.K. Ambati
    Department of Ophthalmology, Medical College of Georgia, Augusta, GA
  • J. Ambati
    Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY
  • Footnotes
    Commercial Relationships  M. Nozaki, None; E. Sakurai, None; B.J. Raisler, None; J.Z. Baffi, None; M. Shibuya, None; B.K. Ambati, None; J. Ambati, Eyetech Pharmaceuticals I; University of Kentucky P.
  • Footnotes
    Support  NEI/NIH, American Geriatrics Society, ARVO/Japan National Society for the Prevention of Blindness
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 470. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Nozaki, E. Sakurai, B.J. Raisler, J.Z. Baffi, M. Shibuya, B.K. Ambati, J. Ambati; Excess Endogenous VEGF–A Suppresses Laser–induced Choroidal Neovascularization via VEGFR–1 . Invest. Ophthalmol. Vis. Sci. 2005;46(13):470.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the mechanistic basis underlying the clinical observation that despite widespread disease in patients with age–related macular degeneration (AMD) there is often but a single focus of CNV, and that CNV often recurs soon after ablation, and to test the hypothesis that endogenous vascular endothelial growth factor–A (VEGF–A) establishes this zone of inhibition in the laser–injury model. Methods: CNV was induced by laser injury in C57BL/6J and Vegfr–1 tyrosine kinase–/– mice, and volumes measured 7 days later by confocal evaluation of Griffonia simplicifolia Isolectin B4 staining of RPE–choroid flamounts. CoCl2, a chemical mimetic of hypoxia, was injected into the vitreous following injury to upregulate VEGF–A. Endogenous VEGF–A also was increased by placing laser spots 2 days or 2 weeks prior to the placement of subsequent laser spots whose CNV response was evaluated. Neutralizing VEGF–A, VEGFR–1, VEGFR–2, or control antibodies were injected into the vitreous following injury. Results: Intravitreous injection of CoCl2 increased VEGF–A levels in the RPE/choroid, which peak 3 days after laser injury, by 88±27% compared to PBS (P < 0.01). CoCl2 decreased laser–induced CNV by 61±10% (P < 0.01). Neutralizing antibodies to VEGF–A and VEGFR–1 restored CNV that was inhibited by CoCl2 (89±13% and 126±23% of control respectively); however, VEGFR–2 blockade did not abrogate CoCl2–induced CNV suppression (46±10% of control). Preexisting injury suppressed CNV volume by 50±8% (P < 0.01) if placed 2 days earlier but not when placed 2 weeks earlier. This zone of inhibition was pronounced in injured areas closer to (600 µm) the preexisting injury than in areas further from (1000 µm) it. Neutralizing VEGF–A antibody but not control IgG abolished the suppression of CNV by preexisting injury (P < 0.05). CNV volume was increased by 37±13% (P < 0.05) in Vegfr–1 tyrosine kinase–/– mice compared to wild–types. Conclusions: Collectively these findings demonstrate that excess endogenous VEGF–A can suppress laser–induced CNV via VEGFR–1 signaling, and support the contention that VEGF–A establishes a zone of angiogenic inhibition. These data also may be used to better guide timing and dosage strategies of anti–VEGF–A therapies in AMD.

Keywords: choroid: neovascularization • growth factors/growth factor receptors • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×